熱門資訊> 正文

Praxis精密药品宣布拟议公开募股

2026-01-07 05:09

Praxis Precision Medicines, Inc.(PRAX) 0

Praxis Precision Medicines (PRAX) announced a proposed public offering of its common stock and, for certain investors, pre-funded warrants in lieu of common stock.
All securities in the offering will be issued and sold by Praxis.
The offering includes a 30-day option for underwriters to purchase up to an additional 15% of the shares (or pre-funded warrants) sold.
Any additional shares would be sold at the public offering price, less underwriting discounts and commissions.

More on Praxis Precision Medicines

Praxis: Priced For Perfection Heading Into 2026
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026
Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。